HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC

Exclusion Criteria

• •1. Known intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma, sarcomatoid HCC, or fibrolamellar carcinoma.
• •2. Concurrent autoimmune diseases, organ/hematopoietic stem cell transplantation history, or other malignancies.
• •3. Impaired consciousness, inability to cooperate with treatment, or active psychiatric disorders.
• •4. Transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), bevacizumab, molecular targeted therapy, atezolizumab, or other PD-1/PD-L1 inhibitors received before enrollment.
• •5. Major surgery, chemotherapy, radiotherapy, or systemic therapy for lesions received within 1 month before enrollment.
• •6. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes (\>10 mg/day prednisone or other equivalent drugs) within 14 days before enrollment.
• •7. Severe esophageal varices or high risk of bleeding assessed by endoscopy.
• •8. Evidence of decompensated liver function, including ascites, gastrointestinal bleeding, or hepatic encephalopathy.
• •9. Severe organ dysfunction in major organs such as the liver, kidneys, heart, lungs, or brain.
• •10. Other contraindications for interventional therapy, molecular targeted therapy, or immunotherapy.
• •11. Inability to undergo scheduled follow-up or concurrent participation in other clinical trials that may interfere with this study.
• •12. Other severe comorbidities deemed by the investigator to jeopardize patient safety or compromise study completion.